Prepared by Imprima de Bussy

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 6-K/A


REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

DECEMBER 15 , 2004


        NOVO NORDISK A/S       
(Exact name of Registrant as specified in its charter)

Novo Allé
DK- 2880, Bagsvaerd
Denmark

(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X]     
     Form 40-F [  ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ]     
      No [X]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________

 

   

This amendment Form 6-K/A filing is being made due to a missing cover page and signature page, the original filing was timely filed on October 27, 2004


Stock Exchange Announcement
Financial statement for the first nine months of 2004

27 October 2004

Novo Nordisk’s operating profit grew by 10% in the first nine months

  • Sales increased by 15% measured in local currencies in the first nine months of 2004. Measured in Danish kroner sales increased by 11%. Sales in the third quarter were positively impacted by increases in US wholesaler inventories.

  • Sales of insulin analogues increased by 87% measured in local currencies.

  • NovoSeven® sales increased by 15% measured in local currencies.

  • Operating profit increased by 10% to DKK 5,203 million, and net profit increased by 4% to DKK 3,615 million. Earnings per share (diluted) increased by 5% to DKK 10.66.

  • Operating profit for the full year 2004 is still expected to grow by slightly more than 5% despite a continued challenging currency environment.

  • Following regulatory consultations in Europe, Novo Nordisk expects to file an application for marketing approval in Europe for the use of NovoSeven® in connection with intracerebral haemorrhages (ICH) by mid-2005.

  • Lars Rebien Sørensen, president & CEO, said: “The strong underlying performance continued in the third quarter, primarily driven by increased sales of insulin analogues and NovoSeven®. We are furthermore very encouraged by the possibility of filing in Europe already next year for the use of NovoSeven® in ICH, a condition for which there today is no effective therapy.”

 

Stock Exchange Announcement No 58 / 2004
Page 1 of 17

Financial statement for the first nine months of 2004

As of 1 January 2004, the accounting policies have been changed to comply with International Financial Reporting Standards (IFRS). The accounting policies used in this unaudited interim financial report are consistent with those used in the Annual Financial Report 2003 except for the changes described in the section 'Adoption of IFRS in 2004' in the Annual Financial Report 2003. This section describes the changes from the historically applied Danish GAAP to IFRS. Free cash flow is defined as cash flow from operating activities plus cash flow from investing activities less net change in marketable securities (>3 months). To facilitate the performance evaluation in the first nine months of 2004, all relevant quarterly numbers and ratios for 2003 and 2004 using IFRS have been made available in the appendices to this announcement.

(Amounts below in DKK million except average number of shares outstanding, earnings per share and full-time employees).

     
% change
 
        9M 2003  
Income statement 9M 2004   9M 2003 to 9M 2004  
             
Sales 21,258   19,188   11%  
             
Gross profit 15,377   13,914   11%  
Gross margin 72.3% 72.5%
           
Sales and distribution costs 6,050   5,506   10%  
Percent of sales 28.5% 28.7%
             
Research and development costs 3,094   2,918   6%  
Percent of sales 14.6% 15.2%
             
Administration costs 1,392   1,355   3%  
Percent of sales 6.5% 7.1%
             
Licence fees and other operating income 362   613   (41%)  
             
Operating profit 5,203   4,748   10%  
Operating margin 24.5% 24.7%
           
Share of profit in associated companies (97)   (144)   (33%)  
Other net financial income 289   692   (58%)  
Profit before tax 5,395   5,296   2%  
             
Net profit 3,615   3,489   4%  
Net profit margin 17.0% 18.2%
           
Other key numbers          
           
Earnings per share (in DKK) – diluted 10.66   10.19   5%  
             
Average number of shares outstanding (million) – diluted 339.3   342.4    
             
Depreciation, amortisation and impairment losses 1,343   1,028   31%  
Capital expenditure 1,907   1,368   39%  
             
Cash flow from operating activities 5,550   5,928   (6%)  
Free cash flow 3,439   4,549   (24%)  
             
Equity 25,654   23,700   8%  
Equity ratio 72.1% 67.4%
Total assets 35,587   35,140   1%  
             
Full-time employees at the end of the period 20,001   18,664   7%  

 

Stock Exchange Announcement No 58 / 2004
Page 2 of 17

Sales development by segments

Sales increased by 15% measured in local currencies. Growth was realised both within the diabetes care and the biopharmaceuticals segments – primarily driven by strategically important products like the insulin analogues NovoRapid® and NovoMix® 30 as well as NovoSeven®.

 
Sales
 
Growth
 
Growth
 
Share of
 
 
9M
 
as
 
in local
 
growth
 
 
2004
 
reported
 
currencies
 
in local
 
 
DKK mn
 
     
currencies
 
The diabetes care segment                
Insulin analogues 3,200   80%   87%   55%  
Human insulin and insulin-related sales 10,524   (1%)   2%   6%  
Oral antidiabetic products 1,250   19%   26%   10%  
Diabetes care – total 14,974   11%   15%   71%  
                 
The biopharmaceuticals segment                
NovoSeven® 3,215   10%   15%   16%  
Growth hormone therapy 1,680   8%   10%   5%  
Other products 1,389   12%   17%   8%  
Biopharmaceuticals – total 6,284   10%   14%   29%  
                 
Total sales 21,258   11%   15%   100%  

Sales growth was realised in all regions, and North America, constituting 27% of total sales, continued to experience strong growth. In October 2004, Novo Nordisk’s US subsidiary, Novo Nordisk Pharmaceuticals, Inc, will for the first time surpass USD 1 billion in accumulated sales within a calendar year.

Diabetes care

Sales of diabetes care products grew by 15% measured in local currencies compared to the first nine months of 2003 and by 11% measured in Danish kroner to DKK 14,974 million.

Insulin analogues, human insulin and insulin-related products

Sales of insulin analogues, human insulin and insulin-related products increased by 14% measured in local currencies and by 11% to DKK 13,724 million measured in Danish kroner. All regions contributed to growth both measured in local currencies and in Danish kroner.

Sales of insulin analogues increased by 87% measured in local currencies and by 80% in Danish kroner to DKK 3,200 million in the first nine months of 2004. Novo Nordisk’s insulin analogue market share continues to increase and is now approaching 30% of the world market. Solid growth rates were realised in all regions with North America as the primary growth driver. Sales of insulin analogues contribute with 55% of the overall growth in local currencies and now constitute more than 20% of Novo Nordisk’s total sales of all insulin products.

Levemir®, Novo Nordisk’s long-acting insulin analogue, has now been launched in 10 European countries, including the UK and Germany. The feedback from all markets about the product has been positive, as patients and physicians appreciate the documented higher degree of predictability than for other long-acting insulins.

 

Stock Exchange Announcement No 58 / 2004
Page 3 of 17

North America
Sales in North America increased by 34% in local currencies in the first nine months of 2004 and by 22% measured in Danish kroner. Sales growth was driven by underlying market growth and market share gains. Sales in the third quarter of 2004 were also influenced by approximately DKK 100 million due to an increase in wholesaler inventories at the end of the quarter. The increased market share is driven by a solid penetration of the insulin analogues NovoLog® and NovoLog® Mix. Novo Nordisk now holds slightly more than one third of the US insulin market and close to 20% of the analogue market.

Europe
Sales in Europe increased by 6% measured in both local currencies and in Danish kroner, with growth being driven by the insulin analogues. Growth in insulin sales continues to be negatively impacted by price-focused healthcare reforms in some countries.

Japan & Oceania
Sales in Japan & Oceania increased by 11% in local currencies and by 10% measured in Danish kroner. Growth is primarily driven by sales of NovoRapid® and NovoRapid® Mix 30, supported by a continued conversion from durable to disposable, prefilled devices.

International Operations
Sales within International Operations increased by 17% in local currencies and by 11% measured in Danish kroner. The main growth driver is sales of human insulin, driven especially by China and Brazil. Insulin analogues continue to add to growth, and Novo Nordisk is now the overall market leader in the analogue segment in the International Operations region.

Oral antidiabetic products
Sales of oral antidiabetic products increased in all regions and in total by 26% measured in local currencies and 19% measured in Danish kroner to DKK 1,250 million. Growth was mainly driven by North America, partly due to an increase in wholesaler inventory levels as well as higher prices.

Biopharmaceuticals

Sales within the biopharmaceuticals segment increased by 14% in local currencies compared to the first nine months of 2003 and by 10% measured in Danish kroner to DKK 6,284 million.

NovoSeven®
Sales of NovoSeven® increased by 15% in local currencies compared to the same period last year. Measured in Danish kroner, sales increased by 10% to DKK 3,215 million. Sales growth for NovoSeven® was primarily driven by Europe and North America.

NovoSeven® sales growth was driven by several factors in the first nine months of 2004. Due to the high penetration within spontaneous bleeds for congenital inhibitor patients, the predominant part of the growth within the inhibitor segment has been generated by treatment of acquired haemophilia patients and usage of NovoSeven® in connection with elective surgery. Treatment of spontaneous bleeds for congenital inhibitor patients remains the largest area of use. In addition, sales are perceived to have been positively affected by increased investigational use of NovoSeven®.

 

Stock Exchange Announcement No 58 / 2004
Page 4 of 17

Growth hormone therapy (Norditropin® and Norditropin® SimpleXx®)
In local currencies sales of Norditropin® and Norditropin® SimpleXx® products increased by 10% compared to the first nine months of 2003. Measured in Danish kroner sales increased by 8% to DKK 1,680 million and were driven by Europe and North America. Sales in Japan were negatively impacted by the government-mandated reduction in reimbursement prices as of April 2004; however, a solid penetration of the prefilled delivery device NordiFlex® has been observed since the launch in July 2004.

Other products
Sales of other products within the biopharmaceuticals segment, which predominantly consists of hormone replacement therapy (HRT) related products, grew by 17% in local currencies and by 12% in Danish kroner to DKK 1,389 million.

Sales growth in the first nine months of 2004 was positively impacted by the change in July 2003 of the US distribution set-up for Novo Nordisk’s HRT products and by the continued market penetration of the low-dose continuous combined product Activella® and the local oestrogen product Vagifem®. For the first nine months of 2004, global sales continued to be negatively impacted by the overall contraction of the HRT market.

Costs

The cost of goods sold increased by 12% to DKK 5,881 million, leaving the gross margin at 72.3%, a decrease from 72.5% in the first nine months of 2003. Gains from an improved product mix as well as productivity increases were more than offset by a negative currency impact of 0.8%.

Total non-production-related costs increased by 8% to DKK 10,536 million. The increase in non-production-related costs reflects especially costs related to sales and distribution, which increased in line with sales. Sales and distribution costs in the third quarter include an impairment charge related to intangible assets. The ratio for research and development costs as a proportion of sales was slightly below 15%, lower than Novo Nordisk’s long-term intended range for research and development costs of 15–16% of sales. This reflects a changed timing of some of the major development projects in the project pipeline.

Net financials

Net financials showed a net income of DKK 192 million in the first nine months of 2004 compared to DKK 548 million in the same period in 2003. Included in net financials are foreign exchange hedging gains, primarily related to the hedging of the US dollar, of DKK 305 million compared to DKK 959 million in the first nine months of 2003. Furthermore, Novo Nordisk has recorded a gain of close to DKK 100 million related to the initiation of a new R&D alliance by ZymoGenetics, Inc in September 2004.

Outlook 2004 and 2005

Novo Nordisk now expects 12-14% growth in sales for 2004 measured in local currencies based on continued market penetration of Novo Nordisk’s insulin analogue portfolio, combined with expectations of increasing NovoSeven® sales. Operating profit for 2004, measured in local currencies and excluding the impact from non-recurring items, is now expected to grow by close to 20%. The expected level of growth in operating profit for 2004 is partly reflecting a lower than normal expenditure ratio for research and development costs relative to sales.

 

Stock Exchange Announcement No 58 / 2004
Page 5 of 17

Despite a continued challenging currency environment, the expectation for sales growth in 2004 measured in Danish kroner remains around 10%, and operating profit is still expected to grow by slightly more than 5%.

For 2004 Novo Nordisk now expects a net financial income of DKK 300 million due to higher expectations for foreign exchange hedging gains as well as non-recurring income related to ZymoGenetics, Inc.

For 2004, Novo Nordisk still expects the tax rate to be 33%, 1 percentage point lower than the tax rate realised in 2003.

Novo Nordisk still expects capital expenditure of DKK 3 billion in 2004. Depreciations, amortisation and impairment losses are now expected to be around DKK 1.9 billion and the free cash flow to be more than DKK 3 billion. These expectations do not include the expected completion around the turn of the year of the restructuring of the AERx® iDMS programme, which will involve an investment of USD 55 million.

Novo Nordisk has hedged expected net cash flows in relation to US dollars, Japanese yen and British pounds for 13, 10 and 7 months, respectively. The financial impact from currency hedging is included in ‘Net financials’.

All of the above expectations are provided that currency exchange rates remain at the current level for the rest of 2004.

Concerning 2005, Novo Nordisk will provide full guidance on expectations in connection with the release of the full-year financial results for 2004, which are scheduled for 28 January 2005. Novo Nordisk’s current ambition for 2005 is to pursue growth in the operating profit of the underlying business, which is aligned with the company’s long-term objective of 15%. The reported level of operating profit growth will, however, be affected by the following two issues: First, growth in operating profit in 2005 will be impacted by an expected lower level of non-recurring income compared to 2004. Second, Novo Nordisk will experience a negative impact on operating profit measured in Danish kroner if currency exchange rates remain at the current level throughout 2005.

Research and development update

The diabetes care segment
Novo Nordisk has now successfully concluded the activities related to the outstanding clinical issues with the US filing of Levemir®. Hence, Novo Nordisk expects to file the relevant amendments to the New Drug Application before year-end, implying that an approval from the US regulatory authorities (FDA) would be expected around mid-2005.

Novo Nordisk has decided to terminate further clinical development of balaglitazone, an oral treatment for patients with type 2 diabetes, as the preclinical results did not suggest a sufficient competitive advantage for balaglitazone compared to similar, marketed products within this therapeutic category.

All clinical and non-clinical data in relation to liraglutide, the once-daily human GLP-1 analogue for the treatment of type 2 diabetes, have over the past months been analysed and discussed with regulatory authorities. Based on this, Novo Nordisk has decided to initiate an additional clinical study comprising approximately 170 patients. The study is intended to increase the

 

Stock Exchange Announcement No 58 / 2004
Page 6 of 17

understanding of the longer-term efficacy and safety profile for the selected therapeutic doses of liraglutide. Furthermore, the study is intended to confirm that certain non-clinical findings are of no relevance to humans. The phase 2b study is expected to be initiated early 2005 and to be followed by a phase 3 clinical trial programme, comprising approximately 3,500 patients, around the turn of 2005/6.

Novo Nordisk has in September obtained full development and manufacturing rights to the AERx® insulin Diabetes Management System (iDMS) programme from Aradigm, Inc. As a consequence, Novo Nordisk will assume all further responsibilities for development and funding of the AERx® iDMS programme. The ongoing pharmacokinetic and pharmacodynamic (PK/PD) study will continue according to plan and is expected to be finalised during the first half of 2005.

The biopharmaceuticals segment

Following regulatory consultations in Europe, Novo Nordisk now expects to file an application for marketing approval in Europe for the use of NovoSeven® in connection with intracerebral haemorrhages (ICH) by mid-2005, followed by an expected six months’ review time by the regulatory authorities. The consultations with the FDA about the US regulatory pathway related to ICH are ongoing, and Novo Nordisk still expects to conclude these before the end of 2004.

A new US research site, focusing on haemostasis and critical care, will be established with the aim of further expanding the R&D effort within this field. The site will be located in New Jersey; an area known for its medical and scientific excellence within the haemostasis field. The site will serve as a centre for early-stage haemostasis R&D and will be staffed by approximately 75 scientists when fully operational by 2007/8.

NordiFlex® has been approved by the FDA. NordiFlex® is a fully integrated disposable delivery system for liquid growth hormone based on FlexPen®, Novo Nordisk’s innovative delivery device, originally developed for insulin injection.

As previously communicated, Novo Nordisk held its first Capital Markets Day on 5 October 2004. At the Capital Markets Day and in a separate stock exchange announcement, Novo Nordisk elaborated on its biopharmaceuticals businesses and provided insights into the company’s research and development activities within the biopharmaceuticals segment.

Equity

Total equity was DKK 25,654 million at the end of the first nine months of 2004, equal to 72.1% of total assets, compared to 72.0% at the end of 2003. Please refer to appendix 5 for further elaboration of changes in equity during 2004.

Holding of treasury shares
As per 27 October 2004, Novo Nordisk A/S and its wholly-owned affiliates owned 19,646,047 of its own B shares, corresponding to 5.54% of the total share capital.

Sustainability issues update

At the Oxford Vision 2020 Summit in September, Novo Nordisk CEO Lars Rebien Sørensen pledged GBP 3 million to the ongoing global fight against chronic diseases, including diabetes. The Oxford Vision 2020 is a global advocacy movement, coorganised by the University of Oxford and Novo Nordisk with the shared goal to prevent and control the global chronic

 

Stock Exchange Announcement No 58 / 2004
Page 7 of 17

disease epidemics. The event was attended by some 90 world-leading public health experts, academics, industry leaders, non-governmental organisations and governments.

In the 2004 update of the Dow Jones Sustainability World Indexes (DJSI World) and Dow Jones STOXX Sustainability Indexes (DJSI STOXX), Novo Nordisk maintains its position, held since 2002, as the leader in the Pharmaceuticals Industry Group. Novo Nordisk’s score of 78% reflects the company’s performance across economic, environmental and social criteria compared to the industry average of 51%.

In August, Novo Nordisk had two accidental releases of materials containing GMOs – genetically modified organisms - at the production site in Bagsværd. The authorities were immediately informed and were satisfied with the prompt response and suggested corrective actions. Subsequently, the Danish Occupational Health authorities inspected the facilities and found no reason to call for actions. The GMOs in question (Class 1) cannot survive outside of their usual protected environment in the laboratory. The incidents were unrelated.

Legal issues update

As of 25 October 2004, Novo Nordisk’s US subsidiary, Novo Nordisk Pharmaceuticals Inc, together with the majority of the hormone therapy product manufacturers, is a defendant in 17 product liability lawsuits. Novo Nordisk’s HRT products (Activella® and Vagifem®) have been sold and marketed in the US since 2000. Until July 2003, the products were sold and marketed in the US exclusively by Pharmacia & Upjohn Corporation (now Pfizer). The proceedings are currently in their preliminary stages; however, Novo Nordisk is not expecting the claims to impact Novo Nordisk’s financial outlook.

Novo Nordisk’s US subsidiary, Novo Nordisk Pharmaceuticals Inc, together with 43 other pharmaceutical companies, is a defendant in a lawsuit brought by the City of New York. The City claims that it was overcharged for drugs used in its Medicaid programme over the last 12 years and is requesting the court to award monetary damages. The lawsuit was filed in August 2004 in the US District Court for the Southern District of New York. The City has not identified any specific basis for its claim that Novo Nordisk overcharged for its products, but it does state that in 2002 it spent approximately USD 1.8 million on Novo Nordisk drugs. The proceedings are currently in their preliminary stages; however, Novo Nordisk is not expecting the claims to impact Novo Nordisk’s financial outlook.

Flamel Technologies SA (‘Flamel’), a French company, has on 8 October 2004 submitted a notice of voluntary dismissal to the court of Delaware, USA, and has thereby withdrawn a lawsuit against Novo Nordisk A/S related to Flamel's so-called ‘Medusa’ technology within the area of long-acting insulin. Flamel had brought the suit against Novo Nordisk A/S in Delaware on 15 June 2004, alleging that Novo Nordisk improperly had used information from Flamel to file patent applications in the US.

Conference call details

At 14:00 CET today, corresponding to 8:00 am New York time, a conference call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors – Conference call’. Presentation material for the conference call will be made available approximately one hour before on the same page.

 

Stock Exchange Announcement No 58 / 2004
Page 8 of 17

Forward-looking statement

The above sections contain forward-looking statements as the term is defined in the US Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations or forecasts of events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisk's products, introduction of competing products, Novo Nordisk's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Risks and uncertainties are further described in reports filed by Novo Nordisk with the US Securities and Exchange Commission (SEC) including the company's Form 20-F, which was filed on 27 February 2004. Please also refer to the section ‘Management of risk in Novo Nordisk’ in the Annual Financial Report 2003. Novo Nordisk is under no duty to update any of the forward-looking statements or to conform such statements to actual results, unless required by law.

Bagsværd 27 October 2004
The Board of Directors

 

Stock Exchange Announcement No 58 / 2004
Page 9 of 17

Contacts for further information

Media:
Outside North America:
Mike Rulis
Tel (direct): (+45) 4442 3573
E-mail: mike@novonordisk.com




In North America:
Susan T Jackson
Tel (direct): (+1) 609 919 7776
E-mail: stja@novonordisk.com

Investors:
Outside North America:
Mogens Thorsager Jensen
Tel (direct): (+45) 4442 7945
E-mail: mtj@novonordisk.com

Palle Holm Olesen
Tel (direct): (+45) 4442 6175
E-mail: phoo@novonordisk.com

In North America:
Christian Kanstrup
Tel (direct): (+1) 609 919 7937
E-mail: cka@novonordisk.com

Further information on Novo Nordisk is available on the company’s internet homepage at the address: novonordisk.com

 

Stock Exchange Announcement No 58 / 2004
Page 10 of 17

Appendix 1:

The Novo Nordisk Group
Quarterly numbers in DKK

(Amounts in DKK million, except number of employees, earnings per share and number of shares outstanding.)                  
                              % change  
      2004       2003           Q3 2003 -  
  Q3   Q2   Q1   Q4   Q3   Q2   Q1   Q3 2004  
 
 
 
 
 
 
 
 
 
                                 
Sales 7,469   7,222   6,567   7,158   6,655   6,477   6,056   12%  
                                 
Gross profit 5,381   5,280   4,716   5,031   4,847   4,677   4,390   11%  
Gross margin 72.0%   73.1%   71.8%   70.3%   72.8%   72.2%   72.5%      
                                 
Sales and distribution costs 2,087   2,037   1,926   2,097   1,880   1,854   1,772   11%  
Percent of sales 27.9%   28.2%   29.3%   29.3%   28.2%   28.6%   29.3%      
Research and development costs 1,081   978   1,035   1,125   1,012   969   937   7%  
Percent of sales 14.5%   13.5%   15.8%   15.7%   15.2%   15.0%   15.5%      
Administrative expenses 496   425   471   482   485   415   455   2%  
Percent of sales 6.6%   5.9%   7.2%   6.7%   7.3%   6.4%   7.5%      
Licence fees and other operating income (net) 59   71   232   423   216   226   171   -73%  
                                 
Operating profit 1,776   1,911   1,516   1,750   1,686   1,665   1,397   5%  
Operating margin 23.8%   26.5%   23.1%   24.4%   25.3%   25.7%   23.1%      
                                 
Share of profit in associated R&D companies 7   (44)   (38)   78   (45)   (41)   (63)   -116%  
Share of profit in other associated companies 5   4   (31)   7   (2)   (2)   9   -350%  
Financial income 125   104   178   438   177   446   421   -29%  
Financial expenses 52   44   22   117   103   116   133   -50%  
Profit before taxation 1,861   1,931   1,603   2,156   1,713   1,952   1,631   9%  
                                 
Net profit 1,248   1,293   1,074   1,413   1,128   1,288   1,073   11%  
                                 
Depreciation, amortisation and impairment losses 576   387   380   553   363   356   309   59%  
Capital expenditure 873   642   392   934   383   519   466   128%  
Cash flow from operating activities 2,490   1,710   1,350   221   2,317   1,437   2,174   7%  
Free cash flow 1,597   956   886   (703)   1,932   910   1,707   -17%  
                                 
Equity 25,654   24,928   24,048   24,887   23,700   22,807   21,829   8%  
Total assets 35,587   34,248   33,838   34,564   35,140   33,103   31,382   1%  
Equity ratio 72.1%   72.8%   71.1%   72.0%   67.4%   68.9%   69.6%      
                                 
Full-time employees at the end of the period 20,001   19,631   19,179   18,756   18,664   18,465   18,221   7%  
                                 
Diluted earnings per share (in DKK)* 3.69   3.81   3.16   4.17   3.31   3.76   3.11   11%  
Average number of shares outstanding (million)*                                
- used for diluted earnings per share 338.2   339.8   339.8   339.1   340.7   342.0   344.6   -1%  
                                 
Sales by business segments:                                
   Insulin analogues 1,262   1,045   893   796   711   576   488   77%  
   Human insulin and insulin-related sales 3,623   3,669   3,232   3,963   3,554   3,666   3,414   2%  
   Oral antidiabetic products (OAD) 449   382   419   390   387   300   363   16%  
   Diabetes care total 5,334   5,096   4,544   5,149   4,652   4,542   4,265   15%  
                                 
   NovoSeven® 1,095   1,093   1,027   940   1,010   996   925   8%  
   Growth hormone therapy 564   562   554   588   520   537   503   8%  
   Hormone replacement therapy 399   392   342   399   361   292   279   11%  
   Other products 77   79   100   82   112   110   84   -31%  
   Biopharmaceuticals total 2,135   2,126   2,023   2,009   2,003   1,935   1,791   7%  
                                 
Sales by geographic segments:                                
   Europe 3,069   3,118   2,894   3,165   2,920   2,935   2,723   5%  
   North America 2,147   1,882   1,769   1,618   1,674   1,501   1,566   28%  
   International Operations 1,171   1,135   980   1,234   1,027   1,058   910   14%  
   Japan & Oceania 1,082   1,087   924   1,141   1,034   983   857   5%  
                                 
Segment operating profit:                                
   Diabetes care 765   954   693   966   755   784   691   1%  
   Biopharmaceuticals 1,011   957   823   784   931   881   706   9%  

*) For Q3 2004 diluted earnings per share/ADR of a nominal value of DKK 2, which include options on Novo Nordisk’s treasury shares with an exercise price below current market value, have been based on an average number of shares of 338,164,982.

 

Stock Exchange Announcement No 58 / 2004
Page 11 of 17

Appendix 2:

The Novo Nordisk Group
Quarterly numbers in EUR

(Amounts in EUR million, except number of employees, earnings per share and number of shares outstanding.)

Key figures are translated into EUR as supplementary information - the translation is based on average exchange rate for income statement      
and exchange rate at the balance sheet date for balance sheet items.  
         
             
 
 
         
         
% change
 
 
2004
 
2003
 
Q3 2003 -
 
 
Q3
 
Q2
 
Q1
 
Q4
 
Q3
  Q2  
Q1
 
Q3 2004
 
 
 
 
 
 
 
 
 
 
 
 
         
             
Sales
1,005
 
970
  882   957  
896
  872   815   12%  
 
 
         
             
Gross profit
723
 
710
  633   673  
652
  630   591   11%  
Gross margin
72.0%
 
73.1%
  71.8%   70.3%  
72.8%
  72.2%   72.5%      
 
 
         
             
Sales and distribution costs
281
 
273
  259   281  
253
  250   238   11%  
Percent of sales
27.9%
 
28.2%
  29.3%   29.3%  
28.2%
  28.6%   29.3%      
Research and development costs
146
 
131
  139   150  
136
  131   126   7%  
Percent of sales
14.5%
 
13.5%
  15.8%   15.7%  
15.2%
  15.0%   15.5%      
Administrative expenses
65
 
60
  62   64  
66
  55   62   2%  
Percent of sales
6.6%
 
5.9%
  7.2%   6.7%  
7.3%
  6.4%   7.5%      
Licence fees and other operating income (net)
8
 
10
  31   56  
30
  30   23   -73%  
 
 
         
             
Operating profit
239
 
256
  204   234  
227
  224   188   5%  
Operating margin
23.8%
 
26.5%
  23.1%   24.4%  
25.3%
  25.7%   23.1%      
 
 
         
             
Share of profit in associated R&D companies
-
 
(4)
  (6)   10  
(6)
  (6)   (8)   -116%  
Share of profit in other associated companies
1
 
-
  (4)   1  
-
  -   1   -350%  
Financial income
17
 
14
  24   59  
23
  60   57   -29%  
Financial expenses
7
 
6
  3   16  
13
  16   18   -50%  
Profit before taxation
250
 
260
  215   288  
231
  262   220   9%  
 
 
         
             
Net profit
168
 
174
  144   189  
152
  174   144   11%  
 
 
         
             
Depreciation, amortisation and impairment losses
77
 
52
  51   74  
48
  48   42   59%  
Capital expenditure
117
 
86
  53   125  
51
  70   63   128%  
Cash flow from operating activities
335
 
230
  181   28  
312
  193   293   7%  
Free cash flow
215
 
128
  119   (96)  
260
  123   230   -17%  
 
 
         
             
Equity
3,447
 
3,348
  3,230   3,343  
3,192
  3,070   2,939   8%  
Total assets
4,782
 
4,600
  4,545   4,643  
4,732
  4,455   4,226   1%  
Equity ratio
72.1%
 
72.8%
  71.1%   72.0%  
67.4%
  68.9%   69.6%      
 
 
         
             
Full-time employees at the end of the period
20,001
 
19,631
  19,179   18,756  
18,664
  18,465   18,221   7%  
 
 
         
             
Diluted earnings per share (in EUR)*
0.49
 
0.52
  0.42   0.56  
0.45
  0.50   0.42   11%  
Average number of shares outstanding (million)*
 
         
             
- used for diluted earnings per share
338.2
 
339.8
  339.8   339.1  
340.7
  342.0   344.6   -1%  
 
 
         
             
Sales by business segments:
 
         
             
   Insulin analogues
170
 
140
  120   106  
96
  77   66   77%  
   Human insulin and insulin-related sales
489
 
491
  435   529  
479
  494   459   2%  
   Oral antidiabetic products (OAD)
60
 
52
  56   53  
52
  40   49   16%  
   Diabetes care total
719
 
683
  611   688  
627
  611   574   15%  
 
 
         
             
   NovoSeven®
147
 
147
  138   125  
136
  135   124   8%  
   Growth hormone therapy
76
 
76
  74   79  
70
  72   68   8%  
   Hormone replacement therapy
53
 
53
  46   54  
48
  39   38   11%  
   Other products
10
 
11
  13   11  
15
  15   11   -31%  
   Biopharmaceuticals total
286
 
287
  271   269  
269
  261   241   7%  
 
 
         
             
Sales by geographic segments:
 
         
             
   Europe
412
 
419
  389   422  
394
  394   367   5%  
   North America
289
 
253
  237   217  
225
  202   211   28%  
   International Operations
158
 
152
  132   165  
138
  143   122   14%  
   Japan & Oceania
146
 
146
  124   153  
139
  133   115   5%  
 
 
         
             
Segment operating profit:
 
         
             
   Diabetes care
103
 
128
  93   129  
101
  106   93   1%  
   Biopharmaceuticals
136
 
128
  111   105  
126
  118   95   9%  

*) For Q3 2004 diluted earnings per share/ADR of a nominal value of DKK 2, which include options on Novo Nordisk’s treasury shares with an exercise price below current market value, have been based on an average number of shares of 338,164,982.

 

Stock Exchange Announcement No 58 / 2004
Page 12 of 17

Appendix 3:

As of 1 January 2004, the accounting policies have been changed to comply with International Financial Reporting Standards (IFRS). The accounting policies used in appendix 1 as well as all other appendices in this interim report are consistent with those used in the Annual Financial Report 2003 except for the changes described in the section 'Adoption of IFRS in 2004' in the Annual Financial Report 2003, which describes the changes from the historically applied Danish GAAP to IFRS.

The Novo Nordisk Group
Consolidated income statement

9M
9M
Q3
Q3
DKK million 2004 2003 2004 2003





Sales 21,258 19,188 7,469 6,655
Cost of goods sold 5,881 5,274 2,088 1,808





Gross profit 15,377 13,914 5,381 4,847
Sales and distribution costs 6,050 5,506 2,087 1,880
Research and development costs 3,094 2,918 1,081 1,012
Administrative expenses 1,392 1,355 496 485
Licence fees and other operating income (net) 362 613 59 216





Operating profit 5,203 4,748 1,776 1,686
Share of profit in associated R&D companies (75) (149) 7 (45)
Share of profit in other associated companies (22) 5 5 (2)
Financial income 407 1,044 125 177
Financial expenses 118 352 52 103





Profit before taxation 5,395 5,296 1,861 1,713
Income taxes 1,780 1,807 613 585





NET PROFIT 3,615 3,489 1,248 1,128
Earnings per share (DKK) 10.71 10.20 3.71 3.31
Earnings per share diluted (DKK) 10.66 10.19 3.69 3.31
Segment sales:
   Diabetes care 14,974 13,459 5,334 4,652
   Biopharmaceuticals 6,284 5,729 2,135 2,003
Segment operating profit:
   Diabetes care 2,412 2,230 765 755
   Biopharmaceuticals 2,791 2,518 1,011 931

 

Stock Exchange Announcement No 58 / 2004
Page 13 of 17

Appendix 4:

The Novo Nordisk Group
Consolidated balance sheet

DKK million
30 Sep 2004
31 Dec 2003
30 Sep 2003
 




 
 
ASSETS  
Long-term assets  
Intangible assets 235 331 380  
Property, plant and equipment 17,142 16,342 16,030  
Investments in associated companies 962 1,040 1,014  
Deferred tax assets 565 579 599  
Long-term financial assets 140 80 55  
TOTAL LONG-TERM ASSETS 19,044 18,372 18,078  
 
Current assets  
Inventories 7,100 6,531 6,543  
Trade receivables 3,770 3,785 3,697  
Tax receivables 173 134 757  
Other receivables 2,028 2,652 1,623  
Marketable securities 525 1,828 1,629  
Cash at bank and in hand 2,947 1,262 2,813  
TOTAL CURRENT ASSETS 16,543 16,192 17,062  




 
TOTAL ASSETS 35,587 34,564 35,140  




 
 
EQUITY AND LIABILITIES  
Share capital 709 709 709  
Treasury shares (39) (33) (29)  
Share premium account 2,565 2,565 2,565  
Retained earnings 22,160 21,037 20,120  
Other comprehensive income 259 609 335  




 
TOTAL EQUITY 25,654 24,887 23,700  
 
Long-term liabilities  
Long-term debt 746 753 1,006  
Deferred tax liabilities 1,539 1,610 1,687  
Provision for pensions 284 222 318  
Other long-term provisions 90 60 39  




 
Total long-term liabilities 2,659 2,645 3,050  
 
Current liabilities  
Short-term debt 436 975 876  
Trade payables 738 1,008 894  
Tax payables 727 643 1,664  
Other current liabilities 4,011 3,366 3,927  
Other short-term provisions 1,362 1,040 1,029  




 
Total current liabilities 7,274 7,032 8,390  
 
TOTAL LIABILITIES 9,933 9,677 11,440  




 
TOTAL EQUITY AND LIABILITIES 35,587 34,564
35,140
 




 

 

Stock Exchange Announcement No 58 / 2004
Page 14 of 17

Appendix 5:

The Novo Nordisk Group
Consolidated statement of changes in equity

Other comprehensive income

Deferred
Exchange
gain/loss
Share
rate
on cash
Other
Share
Treasury
premium
Retained
adjust-
flow
adjust-
DKK million
capital
shares
account
earnings
ments
hedges
ments
Total









9M 2004
Balance at the beginning of the year 709 (33) 2,565 21,037 33 513 63 24,887
Net profit for the period 3,615 3,615
Purchase of treasury shares (7) (1,078) (1,085)
Sale of treasury shares 1 74 75
Dividends declared (1,488) (1,488)
Exchange rate adjustment of investments in
subsidiaries 8 8
Reversal of deferred (gain)/loss on cash flow hedges at
the beginning of the year (513) (513)
Deferred gain/(loss) on cash flow hedges at the end of
the period 153 153
Other adjustments 2 2









Balance at the end of the period 709 (39) 2,565 22,160 41 153 65 25,654
9M 2003
Balance at the beginning of the year 709 (19) 2,565 18,968 27 391 (45) 22,596
Net profit for the period 3,489 3,489
Purchase of treasury shares (10) (1,106) (1,116)
Sale of treasury shares 12 12
Dividends declared (1,243) (1,243)
Exchange rate adjustment of investments in
subsidiaries 16 16
Reversal of deferred (gain)/loss on cash flow hedges at
the beginning of the year (391) (391)
Deferred gain/(loss) on cash flow hedges at the end of
the period 330 330
Other adjustments 7 7









Balance at the end of the period 709 (29) 2,565 20,120 43 330 (38) 23,700

 

Stock Exchange Announcement No 58 / 2004
Page 15 of 17

Appendix 6:

The Novo Nordisk Group
Condensed consolidated statements of cash flow and financial resources

DKK million
9M 2004
9M 2003



Net profit 3,615 3,489
Net reversals with no effect on cash flow 3,705 3,234
Income taxes paid and net interest received (1,662) (783)



Cash flow before change in working capital 5,658 5,940
Net change in working capital (108) (12)



Cash flow from operating activities 5,550 5,928
Net investments in intangible assets and long-term financial assets (204) (11)
Capital expenditure for property, plant and equipment (1,907) (1,368)
Net change in marketable securities (>3 months) 1,303 (1,318)



Total cash flow from investing activities (808) (2,697)
Cash flow from financing activities (2,838) (1,897)
NET CASH FLOW 1,904 1,334
Unrealised gain/(loss) on exchange rates in cash and cash equivalents (22) (8)



Net change in cash and cash equivalents 1,882 1,326
Cash and cash equivalents at the beginning of the year 841 919



Cash and cash equivalents at the end of the period 2,723 2,245
Undrawn committed credit facilities 6,697 8,899



FINANCIAL RESOURCES AT THE END OF THE PERIOD 9,420 11,144
FREE CASH FLOW* 3,439 4,549

*) Cash flow from operating activities + Cash flow from investing activities - Net change in marketable securities (>3 months)

 

Stock Exchange Announcement No 58 / 2004
Page 16 of 17

Appendix 7:

The Novo Nordisk Group
Reconciliations of Danish GAAP to IFRS

Accounting policies
This unaudited interim financial report has been prepared in accordance with International Accounting Standard 34 on Interim Financial Reporting.
As of 1 January 2004, the accounting policies have been changed to comply with International Financial Reporting Standards (IFRS). The date of transition is 1 January 2002. The accounting policies used in this interim financial report are consistent with those used in the Annual Financial Report 2003 except for the changes described in the section 'Adoption of IFRS in 2004' in the Annual Financial report 2003 , which describes the changes from the historically applied Danish GAAP to IFRS. In this interim financial report the presentation and accounting terminology comply with IFRS.
The reconciliation items in the tables below refer to descriptions of the changes in accounting policies due to IFRS adoption mentioned in the section 'Adoption of IFRS in 2004' in the Annual Financial Report 2003 .

Effect of IFRS adoption for the quarterly financial reporting in 2003

DKK Million
Q1
Q2
Q3
Q4





Operating profit – Danish GAAP 1,320 1,619 1,636 1,809
   Accounting for associated R&D companies – reclass. of share of profit or loss 40 36 40 31
   Accounting for associated R&D companies – reclass. of capital (gain)/loss 18 - - (103)
   Provisions for pensions 9 - 1 -
   Borrowing costs – depreciation 10 9 9 10
   Other - 1 - 3
Operating profit – IFRS 1,397 1,665 1,686 1,750
Net profit – Danish GAAP 1,091 1,286 1,130 1,351
   Accounting for associated R&D companies (5) (5) (5) 6
   Market value of currency options (15) 17 (13) 41
   Provisions for pensions 5 - 1 -
   Borrowing costs – depreciation 10 9 9 10
   Borrowing costs – interest expenses as incurred (3) (3) (2) (2)
   Other (10) (16) 8 7
Net profit – IFRS 1,073 1,288 1,128 1,413
Equity – Danish GAAP 22,158 23,159 24,037 25,224
   Accounting for associated R&D companies 40 34 28 31
   Market value of currency options (16) (23) (18) (35)
   Provisions for pensions (32) (30) (29) (36)
   Borrowing costs (282) (278) (273) (268)
   Other (39) (55) (45) (29)
Equity – IFRS 21,829 22,807 23,700 24,887

Effect of IFRS adoption on net profit
         
DKK Million 2003 2002



Net profit – Danish GAAP 4,858 4,095
   Accounting for associated R&D companies (9) (9)
   Market value of currency options 30 50
   Provisions for pensions 6 (7)
   Borrowing costs – depreciation 38 39
   Borrowing costs – interest expenses as incurred (10) (14)
   Other (11) (10)
Net profit – IFRS 4,902 4,144

Effect of IFRS adoption on equity
31 Dec
31 Dec
1 Jan
DKK Million
2003
2002
2002




Equity – Danish GAAP 25,224 22,928 20,137
   Accounting for associated R&D companies 31 47 57
   Market value of currency options (35) (22) (22)
   Provisions for pensions (36) (42) (15)
   Borrowing costs (268) (287) (297)
   Other (29) (28) (31)
Equity – IFRS 24,887 22,596 19,829

 

Stock Exchange Announcement No 58 / 2004
Page 17 of 17

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: DECEMBER 15 , 2004

NOVO NORDISK A/S


Lars Rebien Sørensen, President and Chief Executive Officer